Chromophobe renal cell carcinoma
MONDO:0017885Chromophobe renal cell carcinoma is a rare subtype of renal cell carcinoma, originating from the intercalating cells of the collecting ducts and macroscopically manifesting as a well-circumscribed, highly lobulated, solid tumor that is usually diagnosed at an early stage. It is frequently asymptomatic, or may present with nonspecific symptoms, such as weight loss, fever or fatigue. The classic presentation observed in renal tumors (hematuria, flank pain and palpable mass) is occasionally observed and usually indicates an advanced stage of the disease. It is most frequently sporadic however, several familial cases, associated with Birt-Hogg DubC) syndrome, have been described.
Also known as: chromophobe adenocarcinoma, chromophobe carcinoma, chromophobe carcinoma of kidney, chromophobe carcinoma of the kidney, chromophobe cell carcinoma of kidney, chromophobe cell carcinoma of the kidney, chromophobe renal cell adenocarcinoma, chromophobe renal cell cancer
2789 clinical trials for this condition and its sub-types, 13 tagged with Chromophobe renal cell carcinoma itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Chromophobe renal cell carcinoma
-
New drug combo shows promise for rare kidney cancer
Disease control OngoingThis trial tests a combination of two drugs—anlotinib (a pill that blocks blood vessel growth to tumors) and sintilimab (an IV immunotherapy that helps the immune system attack cancer cells)—as a first treatment for people with advanced non-clear cell renal cell carcinoma, a rare…
Phase 2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Sep 21, 2026 19:00 UTC
-
New combo shows promise for tough kidney cancers
Disease control OngoingThis study tests two drugs, nivolumab and cabozantinib, together in 60 people with advanced or metastatic non-clear cell kidney cancer. The goal is to see how well the combination shrinks tumors. Participants take cabozantinib daily and receive nivolumab infusions every two weeks…
Phase 2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Sep 21, 2026 19:00 UTC
-
Promising combo aims to ease bone pain in advanced kidney cancer
Disease control OngoingThis study tests whether adding a radioactive drug (radium-223) to standard treatment (cabozantinib) helps people with advanced kidney cancer that has spread to the bones. About 134 participants will receive either the combination or cabozantinib alone. The goal is to see if the …
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 02, 2026 00:00 UTC
-
Triple-Drug cocktail shows promise for rare kidney cancers
Disease control OngoingThis study tests whether combining three drugs (cabozantinib, nivolumab, and ipilimumab) can safely slow or shrink advanced kidney cancers that are not the common clear-cell type. About 60 adults with cancers like papillary or chromophobe RCC that have spread will receive the com…
Phase 2 • Sponsor: Bradley A. McGregor, MD • Aim: Disease control
Last updated Jul 25, 2026 00:00 UTC
-
Head-to-Head drug battle for rare kidney cancer
Disease control OngoingThis study compares two FDA-approved drugs, cabozantinib and sunitinib, in people with a rare type of advanced kidney cancer called variant histology renal cell carcinoma. The goal is to see which drug is safer and more effective at slowing cancer growth. About 32 to 84 participa…
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC
-
Supercharged immune cells take on advanced kidney and bladder tumors
Disease control OngoingThis early-phase study tests a new immune therapy for people with advanced kidney or bladder cancer. Researchers take a person's own natural killer cells, train them in the lab to better recognize cancer, and give them back along with a protein that boosts immune activity. The ma…
Early phase 1 • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
New combo shows promise for rare kidney cancers
Disease control OngoingThis study tests a new two-drug combination (cadonilimab plus axitinib) as a first treatment for people with advanced or spread kidney cancer of rare types. About 37 participants will receive the drugs until their disease gets worse or side effects become too severe. The goal is …
Phase 1/2 • Sponsor: Hao Zeng • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC